Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin
- Katsunobu Oyama,
- Sachio Fushida,
- Masahide Kaji,
- Toshiya Takeda,
- Shinichi Kinami,
- Yasuo Hirono,
- Katsuhiro Yoshimoto,
- Kazuhisa Yabushita,
- Hisashi Hirosawa,
- Yuki Takai,
- Tatsuo Nakano,
- Hironobu Kimura,
- Toshiaki Yasui,
- Atsushi Tsuneda,
- Tomoya Tsukada,
- Jun Kinoshita,
- Takashi Fujimura,
- Tetsuo Ohta
- … show all 18 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
We aimed to evaluate the efficacy of a new combination antiemetic therapy comprising aprepitant, granisetron, and dexamethasone in gastric cancer patients undergoing chemotherapy with cisplatin and S-1.
Gastric cancer patients scheduled to receive their first course of chemotherapy with cisplatin (60 mg/m2) and S-1 (80 mg/m2) were treated with a new combination antiemetic therapy aprepitant, granisetron, and dexamethasone on day 1; aprepitant and dexamethasone on days 2 and 3; and dexamethasone on day 4. The patients reported vomiting, nausea, use of rescue therapy, and change in the amount of diet intake, and completed the Functional Living Index-Emesis (FLIE) questionnaire. The primary endpoint was complete response (CR; no emesis and use of no rescue antiemetics) during the overall study phase (0–120 h after cisplatin administration). The secondary endpoints included complete protection (CP; CR plus no significant nausea); change in the amount of diet intake; and the impact of chemotherapy-induced nausea and vomiting (CINV) on daily life during the overall, acute (0–24 h), and delayed (24–120 h) phases.
Fifty-three patients were included. CR was achieved in 88.7, 98.1, and 88.7 % of patients in the overall, acute, and delayed phases, respectively. The corresponding rates of CP were 67.9, 96.2, and 67.9 %. Approximately half of the patients had some degree of anorexia. FLIE results indicated that 79.5 % of patients reported “minimal or no impact of CINV on daily life”.
Addition of aprepitant to standard antiemetic therapy was effective in gastric cancer patients undergoing treatment with cisplatin and S-1.
- Bender CM, McDaniel RW, Murphy-Ende K, Pickett M, Rittenberg CN, Rogers MP, et al. Chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2002;6:94–102. CrossRef
- de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, et al. Patient perceptions of the side effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer. 1997;76:1055–61.
- Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer. 2003;97:2880–6. CrossRef
- Lindley CM, Hirsch JD, O’Neill CV, Transau MC, Gilbert CS, Osterhaus JT. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res. 1992;1:331–40. CrossRef
- Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472–8. CrossRef
- Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol. 2004;15:526–36. CrossRef
- Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs. 1996;52:639–48. CrossRef
- Ettinger DS, Bierman PJ, Bradbury B, Comish CC, Ellis G, Ignoffo RJ, et al. Antiemesis. J Natl Compr Canc Netw. 2007;5:12–33.
- du Bois A, Meerpohl HG, Vach W, Kommoss FG, Fenzl E, Pfleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer. 1992;28:450–7. CrossRef
- Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999;4:191–6.
- Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, et al. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer. 1996;78:2193–8. CrossRef
- Aapro MS, Alberts DS. High-dose dexamethasone for prevention of cisplatin-induced vomiting. Cancer Chemother Pharmacol. 1981;7:11–4. CrossRef
- Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971–94.
- Jantunen IT, Kataja VV, Muhonen TT. An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer. 1997;33:66–74. CrossRef
- Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16:1174–8.
- Tsukada H, Hirose T, Yokoyama A, Kurita Y. Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer. 2001;37:2398–404. CrossRef
- Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003;39:1074–80. CrossRef
- Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112–9. CrossRef
- Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, et al. Aprepitant Protocol 054 Study Group. Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090–8.
- Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17:1000–6. CrossRef
- Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(Supplement 5):v232–43. CrossRef
- Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29: 4189–98.
- JSCO Guidelines for Antiemetics in Oncology 2010. 1st ed. Tokyo: Kanehara shuppan; 2010.
- Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21. CrossRef
- Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer. 2003;11:522–7. CrossRef
- Satou A, Yamazaki T, Nukariya N, Nakamachi M, Shimada K, Matsukawa M, et al. Development of a Japanese version of the FLIE. Gan To Kagaku Ryoho. 2002;29:281–91.
- Stephenson J, Davies A. An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer. 2006;14:348–53. CrossRef
- Tonini G, Vincenzi B, Santini D. New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron. Expert Opin Drug Metab Toxicol. 2005;1:143–9. CrossRef
- Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570–7. CrossRef
- Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone and aprepitant. J Support Oncol. 2006;4:403–8.
- Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer. 2008;112:2080–7. CrossRef
- Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M, et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer. 2009;17:589–94. CrossRef
- Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin
Journal of Gastroenterology
Volume 48, Issue 11 , pp 1234-1241
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Gastric cancer
- Industry Sectors
- Katsunobu Oyama (1)
- Sachio Fushida (1)
- Masahide Kaji (2)
- Toshiya Takeda (3)
- Shinichi Kinami (4)
- Yasuo Hirono (5)
- Katsuhiro Yoshimoto (6)
- Kazuhisa Yabushita (7)
- Hisashi Hirosawa (8)
- Yuki Takai (9)
- Tatsuo Nakano (10)
- Hironobu Kimura (11)
- Toshiaki Yasui (12)
- Atsushi Tsuneda (13)
- Tomoya Tsukada (1)
- Jun Kinoshita (1)
- Takashi Fujimura (1)
- Tetsuo Ohta (1)
- Author Affiliations
- 1. Department of Gastroenterological Surgery, Kanazawa University, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
- 2. Department of Surgery, Toyama Prefectural Central Hospital, Toyama, Japan
- 3. Department of Surgery, Public Central Hospital of Matto Ishikawa, Hakusan, Japan
- 4. Department of General and Digestive Surgery, Kanazawa Medical University, Kahoku, Japan
- 5. First Department of Surgery, University of Fukui, Fukui, Japan
- 6. Department of Surgery, Toyama Rosai Hospital, Uozu, Japan
- 7. Department of Surgery, Takaoka City Hospital, Takaoka, Japan
- 8. Department of Surgery, Toyama City Hospital, Toyama, Japan
- 9. Department of Gastroenterology, Keiju Medical Center, Nanao, Japan
- 10. Department of Surgery, Asanogawa General Hospital, Kanazawa, Japan
- 11. Department of Surgery, NTT West Kanazawa Hospital, Kanazawa, Japan
- 12. Department of Surgery, Kanazawa Social Insurance Hospital, Kanazawa, Japan
- 13. Department of Surgery, Kurobe City Hospital, Kurobe, Japan